These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30036531)

  • 1. Dopaminergic and serotonergic mechanisms in the modulation of pain: In vivo studies in human brain.
    Martikainen IK; Hagelberg N; Jääskeläinen SK; Hietala J; Pertovaara A
    Eur J Pharmacol; 2018 Sep; 834():337-345. PubMed ID: 30036531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal dopamine D2/D3 receptor availability correlates with individual response characteristics to pain.
    Pertovaara A; Martikainen IK; Hagelberg N; Mansikka H; Någren K; Hietala J; Scheinin H
    Eur J Neurosci; 2004 Sep; 20(6):1587-92. PubMed ID: 15355325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain.
    Borg J; Cervenka S; Kuja-Halkola R; Matheson GJ; Jönsson EG; Lichtenstein P; Henningsson S; Ichimiya T; Larsson H; Stenkrona P; Halldin C; Farde L
    Mol Psychiatry; 2016 Aug; 21(8):1077-84. PubMed ID: 26821979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5'UTR polymorphism in the serotonergic receptor HTR3A gene is differently associated with striatal Dopamine D2/D3 receptor availability in the right putamen in Fibromyalgia patients and healthy controls-Preliminary evidence.
    Ledermann K; Hasler G; Jenewein J; Sprott H; Schnyder U; Martin-Soelch C
    Synapse; 2020 May; 74(5):e22147. PubMed ID: 31868947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of striatal dopamine D2/D3 receptor binding potential with pain but not tactile sensitivity or placebo analgesia.
    Martikainen IK; Hagelberg N; Mansikka H; Hietala J; Någren K; Scheinin H; Pertovaara A
    Neurosci Lett; 2005 Mar; 376(3):149-53. PubMed ID: 15721212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential associations between brain 5-HT(1A) receptor binding and response to pain versus touch.
    Martikainen IK; Hirvonen J; Pesonen U; Hagelberg N; Laurikainen H; Tuikkala H; Kajander J; Någren K; Hietala J; Pertovaara A
    J Neural Transm (Vienna); 2009 Jul; 116(7):821-30. PubMed ID: 19533293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of dopamine receptor 2 binding to pain perception in female fibromyalgia patients with and without depression--A [¹¹C] raclopride PET-study.
    Ledermann K; Jenewein J; Sprott H; Hasler G; Schnyder U; Warnock G; Johayem A; Kollias S; Buck A; Martin-Soelch C
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):320-330. PubMed ID: 26708319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a 5-HT1A receptor agonist on striatal dopamine release.
    Bantick RA; De Vries MH; Grasby PM
    Synapse; 2005 Aug; 57(2):67-75. PubMed ID: 15906386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine D2 receptors in modulation of pain in humans: a review.
    Hagelberg N; Jääskeläinen SK; Martikainen IK; Mansikka H; Forssell H; Scheinin H; Hietala J; Pertovaara A
    Eur J Pharmacol; 2004 Oct; 500(1-3):187-92. PubMed ID: 15464032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.
    Davis RE; Vanover KE; Zhou Y; Brašić JR; Guevara M; Bisuna B; Ye W; Raymont V; Willis W; Kumar A; Gapasin L; Goldwater DR; Mates S; Wong DF
    Psychopharmacology (Berl); 2015 Aug; 232(15):2863-72. PubMed ID: 25843749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Descending modulation of neuropathic hypersensitivity by dopamine D2 receptors in or adjacent to the hypothalamic A11 cell group.
    Wei H; Viisanen H; Pertovaara A
    Pharmacol Res; 2009 May; 59(5):355-63. PubMed ID: 19416636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity.
    Hagelberg N; Martikainen IK; Mansikka H; Hinkka S; Någren K; Hietala J; Scheinin H; Pertovaara A
    Pain; 2002 Sep; 99(1-2):273-9. PubMed ID: 12237205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain.
    Sumiyoshi T; Ichikawa J; Meltzer HY
    Neuropsychopharmacology; 1997 Mar; 16(3):183-90. PubMed ID: 9138434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
    Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
    J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder.
    Perani D; Garibotto V; Gorini A; Moresco RM; Henin M; Panzacchi A; Matarrese M; Carpinelli A; Bellodi L; Fazio F
    Neuroimage; 2008 Aug; 42(1):306-14. PubMed ID: 18511303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
    Dhir A; Kulkarni SK
    Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.